Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Most statements are general comparative/guideline-style claims or unspecific descriptions not supported by the provided CRESTOR prescribing information excerpts; only a subset align loosely with on-label concepts (e.g., myopathy/rhabdomyolysis, hepatic enzyme increases, renal impairment/interaction-related dose considerations). Some statements appear to overreach beyond the excerpted label.
Category Scores
Accurate Statements
Rosuvastatin (Crestor) may cause myopathy and rhabdomyolysis; common concerns with statins include muscle aches; statins (rarely) can cause more serious muscle injury.
Section 5.1 (Myopathy and Rhabdomyolysis): CRESTOR may cause myopathy and rhabdomyolysis; risk factors include concomitant drugs and higher dose; discontinue if markedly elevated CK or if myopathy diagnosed/suspected. Section 6 lists Myopathy and Rhabdomyolysis as important adverse reactions.
Common concerns with statins include higher liver enzymes.
Section 5.3 (Hepatic Dysfunction): Increases in serum transaminases have been reported with use of CRESTOR.
Dose and safety considerations can matter for patients with kidney problems.
Section 2.5 (Recommended dosage in Patients with Renal Impairment) and Section 8.6 (Renal Impairment): severe renal impairment dosing limits; renal impairment is a risk factor for myopathy/rhabdomyolysis with monitoring guidance.
Dose and safety considerations can matter for patients with significant drug–drug interaction risk.
Section 2.6 (Dosage Modifications Due to Drug Interactions) and Section 7.1 (Interactions that Increase the Risk of Myopathy and Rhabdomyolysis): examples include avoid concomitant use (e.g., sofosbuvir/velpatasvir/voxilaprevir; gemfibrozil avoid/limit dosing; cyclosporine and others with dose caps).
In patients with increased statin exposure risk, a prescriber may choose a different statin, adjust the dose, or monitor more closely.
Supported in part by label concepts of dosage modifications/limitations for interacting drugs and increased risk with factors such as higher dose and renal impairment (Sections 2.6, 5.1, 8.6).
Crestor is an established brand-name statin.
Indications and labeling refer to CRESTOR as a marketed brand (the label excerpts use the brand name CRESTOR throughout).
Unsupported Statements
“Best” among statins depends on the outcome being optimized for, such as lowering LDL cholesterol, tolerability, reducing cardiovascular events, or minimizing drug interactions and side effects.
Provided label excerpts do not state comparative 'best' guidance or decision criteria across statins.
Crestor (rosuvastatin) is a more potent statin at a given dose than some other statins.
Provided label excerpts do not provide comparative potency vs other statins.
For many people, rosuvastatin can bring LDL down more than some alternatives at equivalent milligram doses.
Provided label excerpts do not include comparative LDL-lowering outcomes vs other statins at equivalent doses.
Rosuvastatin is considered a high-potency statin in everyday prescribing.
Provided label excerpts do not define potency categories or endorse 'high-potency' terminology for prescribing.
Atorvastatin (Lipitor) is an option that is also in the high-potency statin category.
Provided label excerpts for CRESTOR do not discuss atorvastatin or potency category labeling.
Guidelines judge statins by overall cardiovascular risk reduction rather than just LDL cholesterol numbers.
Provided label excerpts describe CRESTOR indications and an LDL-C adjunct role but do not state guideline judgment principles or comparative decision framing.
If two statins at appropriate doses achieve similar LDL lowering, outcomes are usually broadly comparable.
Provided label excerpts do not discuss comparative outcomes between statins based on similar LDL lowering.
Whether Crestor is a good choice can depend on risk factors for side effects such as drug interactions and conditions that increase exposure.
Label supports that drug interactions and risk factors increase myopathy risk and require dosing considerations, but it does not explicitly state 'Crestor is a good choice' or comparative appropriateness language.
Some patients may find certain statins easier to tolerate than others, even within the same potency range.
Provided label excerpts do not address tolerability comparisons across statins.
Dose and safety considerations can matter for patients with other comorbidities that raise statin exposure.
Provided label excerpts specify renal impairment and general risk factors (and interaction-related factors) but do not list 'other comorbidities that raise statin exposure' broadly.
If LDL goals are not met on Crestor at a tolerated dose, clinicians may titrate to a higher dose if safe for the patient.
Provided label excerpt includes 'adjust the dosage' after assessing LDL-C and mentions dosage range and interaction-specific modifications, but it does not provide the specific conditional 'LDL goals not met' titration strategy.
If LDL goals are not met on Crestor at a tolerated dose, clinicians may switch to another statin.
Provided label excerpts do not state switching to another statin after LDL goals are not met.
If LDL goals are not met on Crestor at a tolerated dose, clinicians may add non-statin LDL-lowering therapy.
Provided label excerpts do not discuss adding non-statin therapy in this scenario (beyond existing indications where rosuvastatin is an adjunct to diet/exercise or adjunct to other LDL-lowering therapies in HoFH).
DrugPatentWatch.com tracks brand/generic and patent details for Crestor.
Not supported by the provided prescribing information excerpts (and no such information exists in them).
Contradictions
Low
AI Statement
If LDL goals are not met on Crestor at a tolerated dose, clinicians may titrate to a higher dose if safe for the patient.
Label Reference
No direct contradiction found in provided excerpts.
Important Omissions
Administration instructions details beyond general tablet use (e.g., 'single dose at any time of day, with or without food', 'swallow whole', 'missed dose' guidance, and antacid timing).
Importance:
Moderate
Contraindications (acute liver failure/decompensated cirrhosis; hypersensitivity) were not addressed by the AI statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are unspecific or comparative across statins not supported by the provided CRESTOR label excerpts; while these may not directly contradict dosing/safety content, they could mislead decision-making. Statements about drug interactions and renal-related dosing considerations are directionally consistent with label concepts, but other prescribing/stepwise escalation and switching/add-on therapy claims are not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple comparative/potency/guideline outcome statements are not supported by the provided CRESTOR prescribing information excerpts; several stepwise management statements (titrate/switch/add non-statin after LDL goals) are also not supported by the excerpts.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label excerpts (indications, renal dosing limits, specific drug-interaction dosage modifications/avoidance, and labeled adverse reactions/warnings). Remove or qualify comparative 'best potency' and cross-drug tolerability/outcome generalizations, and avoid non-stated treatment algorithms unless directly present in the label excerpts.